{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:56:36Z","timestamp":1792144596138,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"crossref","award":["Department of Radiology"],"award-info":[{"award-number":["Department of Radiology"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"crossref","award":["Support for Outstanding Academic Research"],"award-info":[{"award-number":["Support for Outstanding Academic Research"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"crossref","award":["SOAR"],"award-info":[{"award-number":["SOAR"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Approval of Locametz and Illuccix kits for the manufacture of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 (gallium Ga68 gozetotide), a PET imaging agent for prostate cancer, as well as the corresponding therapeutic ([\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 Pluvicto), has led to a rapid increase in demand for [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 PET imaging. Radiopharmaceutical manufacturers, using\n                      <jats:sup>68<\/jats:sup>\n                      Ge\/\n                      <jats:sup>68<\/jats:sup>\n                      Ga generators, may decide to adopt Locametz and\/or Illuccix kits, which requires a comparison to select the most suitable kit for day-to-day use. The objective of this article is to compare both kits and provide guidance for selecting one for routine use, as well as evaluate labeling consistency of both kits during routine production. Additionally, we report our experience during 1.5\u00a0years of daily [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 production at our facility using both kits.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Locametz (n\u2009=\u2009181) and Illuccix (n\u2009=\u2009256) kits were prepared using non-silicone coated and silicone-coated needles with\n                      <jats:sup>68<\/jats:sup>\n                      Ga activities ranging from 0.53 to 3.16\u00a0GBq, with a failure rate of 1 in 128 runs for both kits. With Locametz, a 3.7\u00a0GBq generator and 10-min incubation at room temperature gave doses that passed quality control (QC) testing. Use of non-silicone coated needles in the process led to solution discoloration, and QC failure. Additionally, lack of vial inversion led to inconsistent labeling, which improved with subsequent vial agitation. For Illuccix, addition of the acetate buffer to the precursor vial prior to adding the [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]GaCl\n                      <jats:sub>3<\/jats:sub>\n                      simplifies the workflow. The maximum tolerated activity was 1.85\u00a0GBq. Lack of vial inversion led to failures, which were rectified by agitating the vial to properly incorporate the acetate solution with the generator eluate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Both kits benefited from using a syringe pump to elute the\n                      <jats:sup>68<\/jats:sup>\n                      Ge\/\n                      <jats:sup>68<\/jats:sup>\n                      Ga generator, vial agitation, and longer length\/smaller bore silicone coated needles. Both kits have similar workflows, comparable QC outcomes, and result in equivalent clinical images. Thus, the decision between kits will ultimately be determined by production preferences. Since radiopharmacies have an established \u201ckit-based\u201d workflow, Locametz kits with higher allowed activities and longer shelf-life may offer benefits. Conversely, more traditional PET manufacturing facilities might benefit from using Illuccix kits due to compatibility with cyclotron-produced [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]GaCl\n                      <jats:sub>3<\/jats:sub>\n                      allowing for kit batching. Ultimately, the commercial availability of 2 approved kits for production of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 PET has facilitated ready access to this important new imaging agent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-024-00317-4","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:11:28Z","timestamp":1734516688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A comparison of routine [68Ga]Ga-PSMA-11 preparation using Locametz and Illuccix kits"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-9522","authenticated-orcid":false,"given":"Ivan E.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke J.","family":"Morrissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen F.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Dakanali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0450","authenticated-orcid":false,"given":"Peter J. H.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"317_CR1","unstructured":"Advanced Accelerator Applications USA Inc. NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection) [Internet]. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208547s024lbl.pdf. Accessed 28-Oct-2024."},{"issue":"11","key":"317_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/14737159.2016.1243057","volume":"16","author":"M Barrio","year":"2016","unstructured":"Barrio M, Fendler WP, Czernin J, et al. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn. 2016;16(11):1177\u201388. https:\/\/doi.org\/10.1080\/14737159.2016.1243057.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"317_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2967\/jnumed.120.260455","volume":"62","author":"G Carlucci","year":"2021","unstructured":"Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S. 68Ga-PSMA-11 NDA approval: a novel and successful academic partnership. J Nucl Med. 2021;62(2):149\u201355. https:\/\/doi.org\/10.2967\/jnumed.120.260455.","journal-title":"J Nucl Med"},{"issue":"7","key":"317_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/14737159.2024.2383439","volume":"24","author":"J Clore","year":"2024","unstructured":"Clore J, Scott PJH. [68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Expert Rev Mol Diagn. 2024;24(7):565\u201382. https:\/\/doi.org\/10.1080\/14737159.2024.2383439.","journal-title":"Expert Rev Mol Diagn"},{"key":"317_CR5","unstructured":"Novartis Pharmaceuticals Corporation, LOCAMETZ\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection), for intravenous use. [Internet], 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215841s000lbl.pdf. Accessed 28-Oct-2024."},{"key":"317_CR6","unstructured":"Tapp K. Eckert and Ziegler GalliaPharmTM Germanium-68\/Gallium-68 Pharmacy Grade Generator. NRC Licensing Guidance. 2016. https:\/\/www.nrc.gov\/docs\/ML1625\/ML16252A421.pdf. Accessed 28-Oct-2024."},{"issue":"6","key":"317_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","volume":"40","author":"M Eder","year":"2013","unstructured":"Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;40(6):819\u201323. https:\/\/doi.org\/10.1007\/s00259-013-2374-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"317_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ph7070779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, M\u00fcller M, et al. Novel Preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7(7):779\u201396. https:\/\/doi.org\/10.3390\/ph7070779.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"317_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2967\/jnmt.119.241224","volume":"48","author":"P Fang","year":"2020","unstructured":"Fang P, Jacobson MS, Hung JC. Influential Factors in the Preparation of 68Ga-DOTATATE. J Nucl Med Technol. 2020;48(3):263\u20138. https:\/\/doi.org\/10.2967\/jnmt.119.241224.","journal-title":"J Nucl Med Technol"},{"key":"317_CR10","unstructured":"US Food and Drug Administration. NDA 215841, Locametz\/gallium Ga 68 gozetotide Multi-disciplinary Review and Evaluation. Department of Health and Human Services, 2022 [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215841Orig1s000MultidisciplineR.pdf. Accessed 24-Nov-2024."},{"key":"317_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232263","author":"S Hosokawa","year":"2020","unstructured":"Hosokawa S, Shukuya K, Sogabe K, Ejima Y, Morinishi T, Hirakawa E, et al. Novel absorbance peak of gentisic acid following the oxidation reaction. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0232263.","journal-title":"PLoS ONE"},{"key":"317_CR12","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer [Internet]. [https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed 28-Oct-2024."},{"issue":"1","key":"317_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41181-021-00122-3","volume":"6","author":"A Iudicello","year":"2021","unstructured":"Iudicello A, Genovese F, Di Iorio V, Cicoria G, Boschi S. An HPLC and UHPLC-HRMS approach to study PSMA-11 instability in aqueous solution. EJNMMI Radiopharm Chem. 2021;6(1):14. https:\/\/doi.org\/10.1186\/s41181-021-00122-3.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"317_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41181-020-00110-z","volume":"5","author":"IM Jackson","year":"2020","unstructured":"Jackson IM, Lee SJ, Sowa AR, Rodnick ME, Bruton L, Clark M, et al. Use of 55 PET radiotracers under approval of a radioactive drug research committee (RDRC). EJNMMI Radiopharm Chem. 2020;5(1):24. https:\/\/doi.org\/10.1186\/s41181-020-00110-z.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"317_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/1375fmed.2022.812050","volume":"9","author":"N Lepareur","year":"2022","unstructured":"Lepareur N. Cold kit labeling: The future of 68Ga radiopharmaceuticals. Sem Nucl Med. 2022;9: 812050. https:\/\/doi.org\/10.3389\/1375fmed.2022.812050.","journal-title":"Sem Nucl Med"},{"key":"317_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.apradiso.2017.12.010","volume":"133","author":"M Lin","year":"2018","unstructured":"Lin M, Waligorski GJ, Lepera CG. Production of curie quantities of 68Ga with a medical cyclotron via the 68Zn(p, n)68Ga reaction. Appl Radiat Isot. 2018;133:1\u20133. https:\/\/doi.org\/10.1016\/j.apradiso.2017.12.010.","journal-title":"Appl Radiat Isot"},{"key":"317_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0020-1693(94)04012-5","volume":"224","author":"R Ma","year":"1994","unstructured":"Ma R, Motekaitis RJ, Martell AE. Stability of metal ion complexes of N, N\u2019-bis(2-hydroxybenzyl)ethylenediamine-N N\u2019-Diacetic Acid. Inorg Chim Acta. 1994;224:151\u20135. https:\/\/doi.org\/10.1016\/0020-1693(94)04012-5.","journal-title":"Inorg Chim Acta"},{"issue":"1","key":"317_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41181-022-00180-1","volume":"7","author":"BJB Nelson","year":"2022","unstructured":"Nelson BJB, Andersson JD, Wuest F, Spreckelmeyer S. Good practices for 68Ga radiopharmaceutical production. EJNMMI Radiopharm Chem. 2022;7(1):27. https:\/\/doi.org\/10.1186\/s41181-022-00180-1.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"317_CR19","volume-title":"Abeloff\u2019s clinical oncology","author":"JE Niederhuber","year":"2020","unstructured":"Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff\u2019s clinical oncology. 6th ed. Philadelphia, PA: Elsevier; 2020.","edition":"6"},{"key":"317_CR20","unstructured":"Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975\u20132015, National Cancer Institute. Bethesda, MD,\u00a0https:\/\/seer.cancer.gov\/csr\/1975_2015\/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Accessed 28-Oct-2024."},{"key":"317_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nucmedbio.2019.03.002","volume":"74\u201375","author":"MK Pandey","year":"2019","unstructured":"Pandey MK, Byrne JF, Schlasner KN, Schmit NR, DeGrado TR. Cyclotron production of 68Ga in a liquid target: Effects of solution composition and irradiation parameters. Nucl Med Biol. 2019;74\u201375:49\u201355. https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.03.002.","journal-title":"Nucl Med Biol"},{"key":"317_CR22","unstructured":"Telix Pharmaceuticals (US). ILLUCCIX\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection), for intravenous use. [Internet], 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214032s001lbl.pdf. Accessed 28-Oct-2024."},{"key":"317_CR23","unstructured":"European Pharmacopoeia. Monograph no. 3044 \u201cGallium (68Ga) PSMA-11 Injection\u201d. In: European Pharmacopoeia 104. Council of Europe, Strasbourg, France; 2021."},{"issue":"4","key":"317_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41596-021-00662-7","volume":"17","author":"ME Rodnick","year":"2022","unstructured":"Rodnick ME, Sollert C, Stark D, Clark M, Katsifis A, Hockley BG, et al. Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nat Protoc. 2022;17(4):980\u20131003. https:\/\/doi.org\/10.1038\/s41596-021-00662-7.","journal-title":"Nat Protoc"},{"issue":"1","key":"317_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s41181-020-00106-9","volume":"5","author":"ME Rodnick","year":"2020","unstructured":"Rodnick ME, Sollert C, Stark D, Clark M, Katsifis A, Hockley BG, et al. Clark M, Katsifis A, Hockley BG, et al. Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target. EJNMMI Radiopharm Chem. 2020;5(1):25. https:\/\/doi.org\/10.1186\/s41181-020-00106-9.","journal-title":"EJNMMI Radiopharm Chem."},{"issue":"16","key":"317_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2174\/156802610793176738","volume":"10","author":"F Roesch","year":"2012","unstructured":"Roesch F, Riss P. The Renaissance of the 68Ge\/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr Top Med Chem. 2012;10(16):1633\u201368. https:\/\/doi.org\/10.2174\/156802610793176738.","journal-title":"Curr Top Med Chem"},{"issue":"11","key":"317_CR27","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1097\/RLU.0000000000001349","volume":"41","author":"C Sachpekidis","year":"2016","unstructured":"Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, et al. 68Ga-PSMA-11 dynamic PET\/CT imaging in primary prostate cancer. Clin Nucl Med. 2016;41(11):e473\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000001349.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"317_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2191-219X-2-23","volume":"2","author":"M Sch\u00e4fer","year":"2012","unstructured":"Sch\u00e4fer M, Bauder-W\u00fcst U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostatespecific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2(1):1\u201311. https:\/\/doi.org\/10.1186\/2191-219X-2-23.","journal-title":"EJNMMI Res"},{"issue":"1","key":"317_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"317_CR30","unstructured":"Taplin M-E, Smith JA. Initial staging and evaluation of males with newly diagnosed prostate cancer \u2013 In UpToDate (Eds. Lee WR, Richie JP, Yushak M). Updated 2023. https:\/\/www.uptodate.com\/contents\/initial-staging-and-evaluation-of-males-with-newly-diagnosed-prostate-cancer?search=prostatecancerdiagnosis&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2. Accessed 28-Oct-2024."},{"issue":"1","key":"317_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-020-00114-9","volume":"6","author":"H Thisgaard","year":"2021","unstructured":"Thisgaard H, Kumlin J, Langkj\u00e6r N, Chua J, Hook B, Jensen M, et al. Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE. EJNMMI Radiopharm Chem. 2021;6(1):1\u201311. https:\/\/doi.org\/10.1186\/s41181-020-00114-9.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"317_CR32","doi-asserted-by":"publisher","unstructured":"United States Pharmacopeia. General Chapter, \u232971\u232a Sterility Tests. USP-NF, 2024b. United States Pharmacopeia, Rockville, MD. https:\/\/doi.org\/10.31003\/USPNF_M98810_01_01. Accessed 28-Oct-2024.","DOI":"10.31003\/USPNF_M98810_01_01"},{"key":"317_CR33","doi-asserted-by":"publisher","unstructured":"United States Pharmacopeia. General Chapter, \u232985\u232a Bacterial Endotoxins Test. USP-NF, 2024a. United States Pharmacopeia, Rockville, MD. https:\/\/doi.org\/10.31003\/USPNF_M98830_02_01. Accessed 28-Oct-2024.","DOI":"10.31003\/USPNF_M98830_02_01"},{"key":"317_CR34","unstructured":"US Food and Drug Administration. Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. U. S. Department of Health and Human Services, 2008 [Internet]. https:\/\/www.fda.gov\/media\/76338\/download. Accessed 24-Nov-2024."},{"issue":"1","key":"317_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41181-024-00260-4","volume":"9","author":"EA van Brandwijk","year":"2024","unstructured":"van Brandwijk EA, Aalbersberg EA, Hosseini AS, Huitema ADR, Hendrikx JJMA. Automated radiolabelling of [68Ga]Ga-PSMA-11 (gallium (68Ga)-gozetotide) using the Locametz\u00ae kit and two generators. EJNMMI Radiopharm Chem. 2024;9(1):31. https:\/\/doi.org\/10.1186\/s41181-024-00260-4.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"317_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1874471014666210303152908","volume":"15","author":"S Vincenti","year":"2022","unstructured":"Vincenti S, Scotognella T, Bruno S, et al. Media fill test for validation of non-radioactive kit for radiopharmaceutical preparations. Curr Radiopharm. 2022;15(2):104\u20139. https:\/\/doi.org\/10.2174\/1874471014666210303152908.","journal-title":"Curr Radiopharm"},{"key":"317_CR37","unstructured":"Zelefsky M, Morris M, Eastham J. Chapter 70: Cancer of the Prostate. In: DeVita, Hellman, and Rosenberg\u2019s Cancer: Principles and Practice of Oncology (11th ed). Lippincott Williams & Wilkins, Philadelphia, PA, 2019."},{"key":"317_CR38","unstructured":"Eckert & Ziegler. GalliaPharm\u00ae Radionuclide Generator Product Information. [Internet], 2021. http:\/\/www.radiopharmaceuticals.info\/uploads\/7\/6\/8\/7\/76874929\/gallia_pharm.pdf. Accessed 28-Oct-2024."}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-024-00317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-024-00317-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-024-00317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:17:26Z","timestamp":1734520646000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-024-00317-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["317"],"URL":"https:\/\/doi.org\/10.1186\/s41181-024-00317-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5363858\/v1","asserted-by":"object"}]},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this article does not contain any original research studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as this article does not contain any original research studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Provided in the Supplementary Information is a list of Formulation, components of the Locametz and Illuccix kits (Table S1), as well as a list of disposable and non-disposable items used in both the production of Locametz (Table S2) and Illuccix (Table S3). Additionally, required materials for quality control is also provided (Table S4). Provided in an Excel sheet (Appendix A) is the raw data for all 437 PSMA-11 production batches reported and analyzed in this article. The preparer\u2019s names have been replaced with generic names (Person A, Person B, etc.) in the Excel sheet, but reflect the actual radiochemists\u2019s role for each batch.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"IEW, LJM, KKW, AFB and MD disclose no competing interests. PJHS holds equity in Novartis and Telix Pharmaceuticals. Given his role as Associate Editor, Peter J. H. Scott had no involvement in the peer-review of this article and has no access to information regarding its peer-review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}],"article-number":"87"}}